At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study
Sign Up to like & getrecommendations! Published in 2021 at "Depression and Anxiety"
DOI: 10.1002/da.23138
Abstract: It is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real‐world setting and the effects of the medication. read more here.
Keywords: depression; baseline patients; higher burden; patients treated ... See more keywords
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Sign Up to like & getrecommendations! Published in 2022 at "CNS Drugs"
DOI: 10.1007/s40263-022-00916-2
Abstract: The objective of this study was to determine which symptoms measured by the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) improve in those treated with esketamine nasal spray in combination with oral… read more here.
Keywords: placebo plus; treated esketamine; phq; esketamine plus ... See more keywords